If ImClone Systems ' (nasdaq: IMCL - news - people ) Erbitux failed a clinical trial, other monoclonal antibodies, such as Genentech 's (nyse: DNA - news - people ) Rituxan, wouldn't be thrown out.

FORBES: Magazine Article